{"id":207088,"date":"2017-02-11T12:53:20","date_gmt":"2017-02-11T17:53:20","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/foundation-medicine-announces-timing-for-fourth-quarter-and-yahoo-finance.php"},"modified":"2017-02-11T12:53:20","modified_gmt":"2017-02-11T17:53:20","slug":"foundation-medicine-announces-timing-for-fourth-quarter-and-yahoo-finance","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/foundation-medicine-announces-timing-for-fourth-quarter-and-yahoo-finance.php","title":{"rendered":"Foundation Medicine Announces Timing for Fourth Quarter and &#8230; &#8211; Yahoo Finance"},"content":{"rendered":"<p><p>      CAMBRIDGE, Mass.--(BUSINESS WIRE)--    <\/p>\n<p>      Foundation Medicine,      Inc. (FMI) today announced that      financial results for the company's fourth quarter and year      ended December 31, 2016 will be released on Wednesday,      February 22, 2017. The management team will host a conference      call on Wednesday, February 22, 2017, at 4:30 p.m. ET to      discuss the company's financial results and recent      developments. The call can be accessed by dialing      1-855-420-0652 (domestic) or 1-484-365-2939 (international)      five minutes prior to the start of the call and providing the      passcode 61272791.    <\/p>\n<p>      The live, listen-only webcast of the conference call may be      accessed by visiting the investors section of the company's      website at investors.foundationmedicine.com. A replay of the      webcast will be available shortly after the conclusion of the      call and will be archived on the company's website for two      weeks following the call.    <\/p>\n<p>      About Foundation Medicine      Foundation Medicine (FMI) is a      molecular information company dedicated to a transformation      in cancer care in which treatment is informed by a deep      understanding of the genomic changes that contribute to each      patients unique cancer. The company offers a full suite of      comprehensive genomic profiling assays to identify the      molecular alterations in a patients cancer and match them      with relevant targeted therapies, immunotherapies and      clinical trials. Foundation Medicine's molecular information      platform aims to improve day-to-day care for patients by      serving the needs of clinicians, academic researchers and      drug developers to help advance the science of molecular      medicine in cancer. For more information, please visit      <a href=\"http:\/\/www.FoundationMedicine.com\" rel=\"nofollow\">http:\/\/www.FoundationMedicine.com<\/a> or follow      Foundation Medicine on Twitter (@FoundationATCG).    <\/p>\n<p>      Foundation Medicineis a      registered trademark of Foundation Medicine, Inc.    <\/p>\n<p>      View source version on      businesswire.com: <a href=\"http:\/\/www.businesswire.com\/news\/home\/20170206005255\/en\/\" rel=\"nofollow\">http:\/\/www.businesswire.com\/news\/home\/20170206005255\/en\/<\/a>    <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read the original post: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/foundation-medicine-announces-timing-fourth-113000655.html\" title=\"Foundation Medicine Announces Timing for Fourth Quarter and ... - Yahoo Finance\">Foundation Medicine Announces Timing for Fourth Quarter and ... - Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc. (FMI) today announced that financial results for the company's fourth quarter and year ended December 31, 2016 will be released on Wednesday, February 22, 2017. The management team will host a conference call on Wednesday, February 22, 2017, at 4:30 p.m.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/foundation-medicine-announces-timing-for-fourth-quarter-and-yahoo-finance.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[26],"tags":[],"class_list":["post-207088","post","type-post","status-publish","format-standard","hentry","category-molecular-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/207088"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=207088"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/207088\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=207088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=207088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=207088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}